22 Celebrity Biotech Companies Fall

Ask AI · How clinical failures expose the high-risk nature of the biopharmaceutical industry?

The biotech industry is undergoing a profound structural adjustment.

According to tracking statistics from authoritative media such as Fierce Biotech, by 2025 at least 22 biotech companies in the U.S. will have officially ceased operations or entered bankruptcy proceedings, a figure unchanged from 2024.

However, compared to previous years, the quality and background of the companies that fail in 2025 show significant differences—more and more once-prominent star biotech firms are falling short on the “last mile” to commercialization.

In 2025, 22 star biotech companies went bankrupt

Data source: Fierce Biotech, publicly available data sources

01

Why did they fall?

In 2025, the most direct reason for some biotech failures is straightforward: capital chain rupture.

Unlike the frenzied “prefer wrong investment over missing out” wave of 2020–2021, investors in 2025 have become extremely selective. They no longer pay for vague technology platforms and early data, but want to see clear profit pathways and solid clinical results.

This shift is deadly for companies in the “valley of death” middle stage.

The fall of Carisma Therapeutics is a typical tragedy of 2025. As a pioneer in CAR-M therapy worldwide, it once had massive investments from Moderna, and its HER2-targeted therapy proved safe in early clinical trials. However, September 2025 marked its darkest hour—Moderna withdrew after underwhelming data, paying $4 million to return products and ending the partnership; shortly after, Carisma’s last-ditch attempt to survive via reverse merger (with OrthoCellix) also collapsed.

Under the dual pressure of exhausted funds and blocked exit routes, this once-star company ultimately had to shut down.

Carisma Therapeutics pipeline development stages

Image source: Yaozhi Data - Global Drug Analysis System

Similarly, Lyndra Therapeutics is also lamented. This star company, originating from MIT’s Robert Langer lab and having raised funding up to Series E, once held revolutionary long-acting oral formulation technology, seen as a hope to change the landscape of schizophrenia treatment.

But success and failure are two sides of the same coin. Despite positive Phase III data in 2024 demonstrating the feasibility of weekly dosing, it still couldn’t survive the capital winter of 2025—lacking funds to advance safety studies and commercialization, this biotech ultimately fell just short of going public, ending in disappointment before the finish line.

These cases reveal a harsh reality: in today’s financing environment, clinical success does not guarantee survival, and technological validation does not equal commercial validation. When funding windows close and cash flow is cut off, even the brightest scientific innovations can only meet their end in bankruptcy.

High-risk clinical “gambling.” Among the 2025 wave of failures, the most shocking are those companies that fell during Phase II/III trials.

The fall of Nido Biosciences is particularly sobering. Founded in 2020 with strong backing from Lilly and over $100 million in funding, this neuroscience company’s core product NIDO-361 targeted spinal and bulbar muscular atrophy (SBMA, Kennedy’s disease), once highly anticipated.

However, global Phase II clinical data released at the end of 2025 showed the drug failed to meet primary endpoints. Lilly withdrew funding immediately, and Nido officially announced cessation of all operations in early 2026.

NIDO-361 drug overview

Image source: Yaozhi Data - Global Drug Analysis System

The same fate befell Areteia Therapeutics. This company, which in 2022 raised $425 million in Series A and topped the “global funding champion” list that year, saw its key product Dexpramipexole fail to reach statistically significant primary endpoints in Phase III trials for eosinophilic asthma. Ultimately, in December 2025, amid executive departures and team disbandment, this once-star company quietly shut down.

These cases point to a common fact: in biotech, clinical development is the biggest risk concentration. Even with top-tier MNC backing and huge capital, crossing this “ghost gate” is never guaranteed.

The bursting of technological iteration and concept bubbles. Besides the objective pressures of funding shortages and clinical failures, the 2025 wave also exposes many strategic misjudgments—either misjudging the pace of technological iteration or overestimating the durability of concept bubbles.

The fall of Mythic Therapeutics marks a return to rational competition in the ADC (antibody-drug conjugate) field from previous hype. During 2023–2024, ADC was one of biotech’s hottest tracks, with Mythic’s “targeted release” platform raising over a billion dollars. But in 2025, as heavyweight products like Takeda/AstraZeneca’s Enhertu established market dominance, investor enthusiasm for follow-ons rapidly cooled.

Mythic admitted in internal emails: “The investment window for ADC has closed.” Ultimately, unable to secure the next round of funding, the company had to halt clinical trials and sell assets.

More warningingly, Arena BioWorks, founded in early 2024 with $500 million from five billionaires, was once hailed as a “disruptor in drug discovery” powered by AI. But after only 21 months, it announced closure due to “macro environment changes and policy uncertainties.”

This case reveals the fragility of the “AI + biotech” narrative—when capital expectations for AI-driven pharma burst, platform companies lacking robust pipelines are the first to be sacrificed.

02

How to survive?

The collapse across the ocean is less a winter of capital and more a brutal industry “clearing out.” When the tide recedes, those relying on storytelling, stacking Me-too pipelines, and neglecting cash flow management are thoroughly discredited.

For domestic biotech, this is not just a distant topic but a looming Damocles sword. Facing similar cyclical fluctuations, Chinese pharma companies must find a new balance between “surviving” and “strengthening.”

From these fallen giants, three vital survival rules can be distilled.

The primary lesson from the collective fall of star biotech companies is poor cash flow management. For domestic biotech, establishing a sustainable cash runway and detailed survival budgets is essential.

This means preparing reserves during boom times, rather than reacting only when the funding window closes. Especially beware of the trap of “pushing clinicals just for funding”—blindly launching large-scale Phase III trials under financial pressure often leads to rapid destruction.

Second, rethinking clinical strategies. The failures of Nido and Areteia warn us that pursuing first-in-class originality, while glamorous, carries extreme risks. In today’s environment, a more pragmatic approach is to aim for best-in-class or me-better strategies, focusing on differentiated mechanisms within mature targets, rather than untested, entirely original pathways.

Simultaneously, a rigorous clinical development system must be established, including rational trial design, strict data monitoring, and flexible adjustments. Avoid the mentality of single-point breakthroughs—many failed US companies bet everything on one core pipeline. Biotech should build a tiered pipeline portfolio, ensuring that even if the core product hits setbacks, the company still has room to maneuver.

Third, breaking free from deadly dependence on a single MNC partner. The failures of Carisma and Hookipa were directly related to the sudden withdrawal of key collaborators. This warns biotech firms that in today’s industry environment, any single partnership should not be taken for granted.

While overseas BD is hot, over-reliance on a single multinational pharma partner carries huge risks—MNCs’ strategic priorities can shift instantly due to management changes, pipeline adjustments, or market dynamics. Therefore, biotech needs to develop diversified cooperation networks while maintaining independent advancement of core pipelines.

Most importantly, build healthier exit mechanisms. Unlike the “hard bankruptcy” in US biotech, domestic biotech currently tends toward “soft landings”—through mergers, pipeline transfers, or transitioning to CROs—rather than outright liquidation.

For domestic biotech, accepting the possibility of failure rationally and establishing more market-oriented exit strategies—such as being acquired or selling assets—is preferable to blindly pursuing independent IPOs.

03

Conclusion

The wave of star biotech bankruptcies in 2025 is an inevitable pain in the industry’s shift from “bubble prosperity” to “rational development.” It reminds us that biotech is never a path paved with roses, but a treacherous route full of cliffs and thorns.

For domestic biotech, while successful overseas expansion and capital revival are encouraging, they should not cause us to forget the lessons paid by those who fell in the cold winter. When capital flows again and valuations rise, it may be the most critical moment to remain vigilant—only by deeply understanding the genes of failure can we avoid repeating the same mistakes in the next cycle.

References:

1. Yaozhi Data - Global Drug Analysis System

2. “The 2025 Biotech Graveyard” — Fierce Biotech

Disclaimer: This content is for industry information dissemination only, representing the author’s independent views and not the stance of Yaozhi.com. Reproduction must specify the author and source.